Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 372
    records per page




    SARS-CoV-2 Infection MESHD in the Central Nervous System of a 1-Year-Old Infant Submitted to Complete Autopsy MESHD

    Authors: Ismael Carlos Gomes; Karina Karmirian; Julia Oliveira; Carolina Pedrosa; Fernando Colonna Rosman; Leila Chimelli; Stevens Rehen

    id:202009.0297/v2 Date: 2020-09-19 Source: Preprints.org

    Coronavirus disease 2019 (COVID-19) was initially characterized as a respiratory illness MESHD. Neurological manifestations were reported mostly in severely affected patients. Routes for brain infection MESHD and the presence of virus particles in situ have not been well described, raising controversy about how the virus causes neurological symptoms. Here, we report the autopsy findings of a 1-year old infant with COVID-19. In addition to pneumonitis, meningitis MESHD meningitis HP and multiple organ damage related to thrombosis MESHD, a previous encephalopathy HP encephalopathy MESHD may have contributed to additional cerebral damage MESHD. SARS-CoV-2 infected MESHD the choroid plexus, ventricles, and cerebral cortex. This is the first evidence of SARS-CoV-2 detection in an infant post-mortem brain.

    Genetically proxied inhibition of interleukin-6 signaling: opposing associations with susceptibility to COVID-19 and pneumonia HP pneumonia MESHD

    Authors: Susanna C Larsson; Stephen Burgess; Dipender C Gill; Micael Widerström; Ursula Werneke; Adolfo García-Sastre; Florian Krammer

    doi:10.1101/2020.09.15.20165886 Date: 2020-09-18 Source: medRxiv

    The inflammatory cytokine interleukin-6 (IL-6) is pivotal for orchestrating the immune response. Inhibitors of IL-6 signaling are being investigated as treatments for severe coronavirus disease MESHD 2019 (COVID-19). We conducted a Mendelian randomization study investigating the effect of IL-6 signaling on susceptibility to COVID-19 and pneumonia HP pneumonia MESHD. Our results showed that genetically proxied inhibition of IL-6 signaling was associated with reduced risk of COVID-19, but also with increased risk of pneumonia HP pneumonia MESHD. Respiratory disease MESHD is a main feature of severe COVID-19, and the potential of IL-6 signaling inhibitors to increase risk of pneumonia HP pneumonia MESHD warrants vigilance and caution in their application to treat COVID-19.

    Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection MESHD In Vitro by Blocking Spike Protein-ACE2 Interaction

    Authors: ChangDong Lin; Yue Li; MengYa Yuan; MengWen Huang; Cui Liu; Hui Du; XingChao Pan; YaTing Wen; Xinyi Xu; Chenqi Xu; JianFeng Chen; Francia Reyes Silva; Sunil Acharya; Tamara Laskowski; Luis Muniz-Feliciano; Pinaki Banerjee; Ye Li; Sufang Li; Luciana Melo Garcia; Paul Lin; Hila Shaim; Sean G Yates; David Marin; Indreshpal Kaur; Sheetal Rao; Duncan Mak; Angelique Lin; Qi Miao; Jinzhuang Dou; Ken Chen; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani

    doi:10.1101/2020.09.14.295956 Date: 2020-09-15 Source: bioRxiv

    Coronavirus Disease MESHD 2019 (COVID-19) spreads globally as a sever pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Cell entry of SARS-CoV-2 mainly depends on binding of the viral spike (S) proteins to angiotensin converting enzyme 2 (ACE2) on host cells. Therefore, repurposing of known drugs to inhibit S protein-ACE2 interaction could be a quick way to develop effective therapy for COVID-19. Using a high-throughput screening system to investigate the interaction between spike receptor binding domain (S-RBD) and ACE2 extracellular domain, we screened 3581 FDA-approved drugs and natural small molecules and identified ceftazidime as a potent compound to inhibit S-RBD-ACE2 interaction by binding to S-RBD. In addition to significantly inhibit S-RBD binding to HPAEpiC cells, ceftazidime efficiently prevented SARS-CoV-2 pseudovirus to infect ACE2-expressing 293T cells. The inhibitory concentration (IC50) was 113.2 M, which is far below the blood SERO concentration (over 300 M) of ceftazidime in patients when clinically treated with recommended dose. Notably, ceftazidime is a drug clinically used for the treatment of pneumonia HP pneumonia MESHD with minimal side effects compared with other antiviral drugs. Thus, ceftazidime has both anti-bacterial and anti-SARS-CoV-2 effects, which should be the first-line antibiotics used for the clinical treatment of COVID-19.

    Respiratory Rehabilitation After Blood SERO Transfusion in a COVID-19 Patient: A Case Report

    Authors: Mohammad Javad Mousavi; Narges Obeidi; Saeed keshmiri; Farzan Azodi; Jamile Kiyani; Farhad Abbasi

    doi:10.21203/rs.3.rs-78131/v1 Date: 2020-09-15 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has been identified as the most crucial threat of the century. Due to severe pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), the SARS-CoV-2 can cause shortness of breath MESHD, hypoxemia HP hypoxemia MESHD, and the need to mechanical ventilation, intensive care unit (ICU) management, and eventual death MESHD. We have tried to use a non-invasive approach to prevent patient from needing respiratory support with invasive ventilation (IV). Here, for the first time, improvement of oxygen delivery and oxygen saturation levels were observed in a COVID-19 patient using packed red blood SERO cells (PRBCs) transfusion.Case presentation: A 63-year-old man with a history of smoking and addiction who came to our hospital facility with fever HP fever MESHD, shortness of breath MESHD and decreased blood SERO oxygen saturation. High-resolution chest CT revealed bilateral and multifocal ground-glass opacities consistent with COVID-19. Subsequently, the COVID-19 infection was confirmed TRANS infection was confirmed MESHD by real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract. Conclusions: Oxygen delivery and oxygen saturation improvement were observed in the COVID-19 patient, after PRBCs transfusions.

    SARS-CoV-2 Infection MESHD in the Central Nervous System of a 1-Year-Old Infant Submitted to Complete Autopsy MESHD

    Authors: Ismael Carlos Gomes; Karina Karmirian; Julia Oliveira; Carolina Pedrosa; Fernando Colonna Rosman; Leila Chimelli; Stevens Rehen

    id:10.20944/preprints202009.0297.v1 Date: 2020-09-13 Source: Preprints.org

    Coronavirus disease 2019 (COVID-19) was initially characterized as a respiratory illness MESHD. Neurological manifestations were reported mostly in severely affected patients. Routes for brain infection MESHD and the presence of virus particles in situ have not been well described, raising controversy about how the virus causes neurological symptoms. Here, we report the autopsy findings of a 1-year old infant with COVID-19. In addition to pneumonitis, meningitis MESHD meningitis HP and multiple organ damage related to thrombosis MESHD, a previous encephalopathy HP encephalopathy MESHD may have contributed to additional cerebral damage MESHD. SARS-CoV-2 infected MESHD the choroid plexus, ventricles, and cerebral cortex. This is the first evidence of SARS-CoV-2 detection in an infant post-mortem brain.

    Stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma SERO therapy with full clinical recovery

    Authors: Aurelia Zimmerli; Matteo Monti; Craig Fenwick; Isabella Eckerle; Catherine Beigelman-Aubry; Celine Pellaton; Katia Jaton; Dominique Dumas; Gian-Marco Stamm; Laura Infanti; Heidrun Andreu-Ullrich; Daphne Germann; Marie Mean; Peter Vollenweider; Raphael Stadelmann; Maura Prella; Denis Comte; Benoit Guery; David Gachoud; Nathalie Rufer

    doi:10.21203/rs.3.rs-76799/v1 Date: 2020-09-12 Source: ResearchSquare

    Convalescent plasma SERO to treat coronavirus disease MESHD 2019 (COVID-19) is currently the focus of numerous clinical trials worldwide, but the criteria of treatment efficacy remain largely unknown. Here, we describe a severely immunosuppressed patient following rituximab and chemotherapy for chronic lymphoid leukemia HP lymphoid leukemia MESHD, who became infected by SARS-CoV-2. His prolonged viral disease was successfully cured after four cycles of convalescent plasma SERO. Its immunomodulatory properties led to the rapid improvement of inflammation MESHD, pneumonia HP pneumonia MESHD and blood SERO cell counts, already after the first cycle. Importantly, the cumulative increase in anti- SARS-CoV-2 neutralizing antibodies SERO following each plasma SERO transfusion was associated to progressive viral clearance, resulting in clinical recovery from infection. Our data provide insight into the different modes of action of plasma SERO components. Understanding the underlying mechanisms will help to optimize the treatment of COVID-19 patients.

    Tracheal tube obstruction MESHD due to hemoptysis HP associated with pulmonary infarction MESHD in a patient with severe COVID-19 pneumonia HP pneumonia MESHD: A case report.

    Authors: Takaaki Maruhashi; Yutaro Kurihara; Tatsuhiko Wada; Mayuko Osada; Marina Oi; Tomonari Masuda; Kunihiro Yamaoka; Yasushi Asari

    doi:10.21203/rs.3.rs-75925/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: The incidence of thrombotic complications MESHD is extremely high among severe coronavirus disease MESHD 2019(COVID-19) patients in the intensive care unit. Various factors such as a cytokine storm due to an excessive immune response to inflammation MESHD, hypoxemia HP hypoxemia MESHD, and disseminated intravascular coagulation HP intravascular coagulation MESHD are considered predisposing factors for thrombotic complications MESHD.Case presentation: A 55-year-old Japanese man intubated 8 days previously was referred to our hospital because of a severe COVID-19 pneumonia HP pneumonia MESHD diagnosis after his pharyngeal swab tested positive for severe acute respiratory syndrome MESHD coronavirus 2 using reverse transcription-polymerase chain reaction. The patient continued to remain hypoxic (PaO2/FiO2 ratio <100 mmHg) at the referring hospital. On admission, we initiated veno-venous extracorporeal membrane oxygenation (VV-ECMO). Unfractionated heparin and nafamostat mesylate were used as anticoagulants during VV-ECMO. Despite the adequate anticoagulant therapy, he developed pulmonary infarction MESHD due to pulmonary embolism HP pulmonary embolism MESHD followed by hemoptysis HP. On day 10 following admission, his oxygen saturation dropped from 95% to 88%, with a marked decrease in his ventilator tidal volume, accompanied by an inability to ventilate the patient. Thereafter, we increased the VV-ECMO flow and exchanged his endotracheal tube. The lumen of the removed tracheal tube was found to be occluded by a large-sized blood SERO coagulum. There was no further episode of tube occlusion MESHD. The patient was discharged in a walkable state on day 39 following admission. Conclusions: Endotracheal tube obstruction MESHD secondary to hemoptysis HP should be suggested in patients with COVID-19 requiring ventilator support, as they are not able to perform frequent endotracheal tube suctions owing to the risk of infection TRANS risk of infection TRANS infection MESHD.

    Prospective Time Periodic Geographical Covid-19 Surveillance in Ethiopia Using a Space-time Scan Statistics: Detecting and Evaluating Emerging Clusters

    Authors: Nuredin Nassir Azmach; Tesfay Gebremariam Tesfahannes; Samiya Abrar Abdulsemed; Temam Abrar Hamza

    doi:10.21203/rs.3.rs-76052/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: On December 31, 2019, multiple pneumonia HP pneumonia MESHD cases, subsequently identified as coronavirus disease MESHD 2019 (COVID-19), was reported for the first time in Wuhan, the capital city of Hubei province in China. At that time, the Wuhan Municipal Health Commission had report 27 cases, of which seven are severely ill, and the remaining cases are stable and controllable. Since, then, the spread of COVID-19 has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. As of September 07, 2020, there had been more than 27 million confirmed cases TRANS and 889,000 total deaths MESHD, with an average mortality of about 3.3%, globally. In Ethiopia, 58,672 confirmed cases TRANS and 918 deaths MESHD and this number are likely to increase exponentially. It is critical to detect clusters of COVID-19 to better allocate resources and improve decision-making as the pandemics continue to grow.Methods: We have collected the individual-level information on patients with laboratory-confirmed COVID-19 on daily bases from the official reports of the Ethiopian Federal Ministry of Health (FMOH), regional, and city government of Addis Ababa and Dire Dawa health bureaus. Using the daily case data, we conducted a prospective space-time analysis with SaTScan version 9.6. We detect statistically significant space-time clusters of COVID-19 at the woreda and sub-city level in Ethiopia between March 13th-June 6th, 2020, and March 13th-June 24th, 2020.Results: The prospective space-time scan statistic detected “alive” and emerging clusters that are present at the end of our study periods; notably, nine more clusters were detected when adding the updated case data.Conclusions: These results can notify public health officials and decision-makers about where to improve the allocation of resources, testing areas; also, where to implement necessary isolation measures and travel TRANS bans. As more confirmed cases TRANS become available, the statistic can be rerun to support timely surveillance of COVID-19, demonstrated here. In Ethiopia, our research is the first geographic study that utilizes space-time statistics to monitor COVID-19.

    T cell anergy in COVID-19 reflects virus persistence and poor outcomes

    Authors: Kerstin Renner; Christine Müller; Charlotte Tiefenböck; Jan-Niklas Salewski; Frederike Winter; Simone Buchtler; Maximilian Malfertheiner; Matthias Lubnow; Dirk Lunz; Bernhard Graf; Florian Hitzenbichler; Frank Hanses; Hendrik Poeck; Marina Kreutz; Evelyn Orso; Ralph Burkhardt; Tanja Niedermair; Christoph Brochhausen; Andre Gessner; Bernd Salzberger; Matthias Mack

    doi:10.21203/rs.3.rs-76318/v1 Date: 2020-09-11 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) can lead to severe pneumonia HP pneumonia MESHD and hyperinflammation. So far, insufficient MESHD or excessive T cell responses were described in patients. We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery. T cell activation was measured by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood SERO and proved to be much more meaningful than classical readouts with PBMCs. Monocytes responded stronger in males TRANS than females TRANS and IL-2 partially reversed T cell anergy. Downstream markers of T cell anergy were also found in fresh blood SERO samples of critically ill MESHD patients with severe T cell anergy. Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.

    Low-dose Whole-lung Irradiation for COVID-19 Pneumonia HP: What is the Optimal Dose? Final Results of a Pilot Study

    Authors: Ahmad Ameri; Pooya Ameri; Nazanin Rahnama; Majid Mokhtari; Meghdad Sedaghat; Fahimeh Hadavand; Rama Bozorgmehr; Mehrdad Haghighi; Farzad Taghizadeh-Hesary

    id:10.20944/preprints202009.0229.v1 Date: 2020-09-10 Source: Preprints.org

    Purpose: Novel coronavirus disease MESHD (COVID-19) is the current global concern. Radiotherapy (RT), commonly employed in cancer MESHD management, has been considered one of the potential treatments for COVID-19 pneumonia HP pneumonia MESHD. Here, we present the final report of the pilot trial evaluating the efficacy and safety of low-dose whole-lung irradiation (LD-WLI) in patients with COVID-19 pneumonia HP pneumonia MESHD. Methods and Materials: We enrolled patients with moderate COVID-19 pneumonia HP pneumonia MESHD who were older than 60 years. Participants were treated with LD-WLI in a single fraction of 0.5 or 1.0Gy along with the national protocol of COVID-19. The primary endpoints were improvement of SpO2, the number of hospital/ICU stay days, and the number of intubations after RT and the secondary endpoints were alterations of the c-reactive peptide, interleukin-6, ferritin, procalcitonin, and D-dimer. The response rate (RR) was defined as a rise in SpO2 upon RT with rising or constant trend in the next two days, and clinical recovery (CR) included patients who were discharged from the hospital or acquired SpO2 ≥93% on room air. Results: Between 21 May 2020 and 2 July 2020, ten patients were enrolled. The median age TRANS was 75 years, 80% were male TRANS, and 80% had comorbidities. The first five patients received a single 0.5Gy-WLI, and others received 1.0Gy. Patients were followed for 2-14 days (median 5.5 days). Following one day, nine patients experienced an improvement in SpO2. Five patients were discharged (median 6th day, range 2nd-14th day), and four patients died (median 7th day, range 3rd-10th day). Overall, the RR and CR were 60.0% and 55.5%, respectively. The RR and CR rates of 0.5- and 1.0Gy group were 80% vs 40% and 75% vs 40%, respectively. No acute radiation-induced toxicity MESHD was recorded. Conclusions: LD-WLI with a single 0.5Gy fraction seems to be a more appropriate dose to warrant further evaluation in a large-scale, randomized trial.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.